New horizons with biological response modifiers in haematological malignancies. Satellite symposiumGOLDMAN, John M.Acta haematologica. 1993, Vol 89, issn 0001-5792, SUP1Conference Proceedings

Chronic myeloid leukaemiaGOLDMAN, John M.Baillière's clinical haematology. 1997, Vol 10, Num 2, issn 0950-3536, 252 p.Serial Issue

The role of all-trans-retinoic acid in the treatment of acute promyelocytic leukemiaFENAUX, P.Acta haematologica. 1993, Vol 89, pp 22-27, issn 0001-5792, SUP1Conference Paper

Chronic Myeloid Leukemia: A Historical PerspectiveGOLDMAN, John M.Seminars in hematology. 2010, Vol 47, Num 4, pp 302-311, issn 0037-1963, 10 p.Article

Management decisions in chronic myeloid leukemiaGOLDMAN, John M; MARIN, David.Seminars in hematology. 2003, Vol 40, Num 1, pp 97-103, issn 0037-1963, 7 p.Article

Donor leukocyte infusionsMACKINNON, S.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 357-367, issn 0950-3536Article

Treatment of chronic myeloid leukaemia : some topical questionsGOLDMAN, J. M.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 405-421, issn 0950-3536Article

Allografting for chronic myeloid leukaemiaCLIFT, R. A; ANASETTI, C.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 319-336, issn 0950-3536Article

The chimeric BCR-ABL geneGROFFEN, J; HEISTERKAMP, N.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 187-201, issn 0950-3536Article

International symposium on autografting for chronic myeloid leukaemiaCARELLA, Angelo M; GOLDMAN, John M.Bone marrow transplantation. Supplement (Basingstoke). 1994, Vol 14, Num 3, issn 0951-3078, 88 p.Conference Proceedings

BCR-ABL gene variantsMELO, J. V.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 203-222, issn 0950-3536Article

Chronic myeloid leukemia: Advances in biology and new approaches to treatmentGOLDMAN, John M; MELO, Junia V.The New England journal of medicine. 2003, Vol 349, Num 15, pp 1451-1464, issn 0028-4793, 14 p.Article

Myeloproliferative and myelodysplastic syndromes: the futureGOLDMAN, John M.Hematology/oncology clinics of North America. 2003, Vol 17, Num 5, pp viii-ix, issn 0889-8588, 11 p.Article

Chronic myeloid leukemia : current treatment optionsGOLDMAN, John M; DRUKER, Brian J.Blood. 2001, Vol 98, Num 7, pp 2039-2042, issn 0006-4971Article

Signal transduction pathways involved in BCR-ABL transformationSAWYERS, C. L.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 223-231, issn 0950-3536Article

Interferon-α : results from randomized trialsRICHARDS, S. M.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 307-318, issn 0950-3536Article

Autografting for chronic myeloid leukaemiaO'BRIEN, S. G.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 369-388, issn 0950-3536Article

Assessing residual leukaemiaCROSS, N. C. P.Baillière's clinical haematology. 1997, Vol 10, Num 2, pp 389-403, issn 0950-3536Article

Clinical decisions for chronic myeloid leukemia in the imatinib eraGOLDMAN, John M; MARIN, David; OLAVARRIA, Eduardo et al.Seminars in hematology. 2003, Vol 40, Num 2, pp 98-103, issn 0037-1963, 6 p., SUP2Conference Paper

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaGRINFELD, Jacob; GERRARD, Gareth; O'BRIEN, Stephen et al.British journal of haematology. 2013, Vol 163, Num 5, pp 631-639, issn 0007-1048, 9 p.Article

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsDAGHISTANI, Mustafa; MARIN, David; APPERLEY, Jane F et al.Blood. 2010, Vol 116, Num 26, pp 6014-6017, issn 0006-4971, 4 p.Article

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyIBRAHIM, Amr R; PALIOMPEIS, Christos; DAZZI, Francesco et al.Blood. 2010, Vol 116, Num 25, pp 5497-5500, issn 0006-4971, 4 p.Article

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia : Incidence of Sustained Responses in an Intention-to-Treat AnalysisDE LAVALLADE, Hugues; APPERLEY, Jane F; MARIN, David et al.Journal of clinical oncology. 2008, Vol 26, Num 20, pp 3358-3363, issn 0732-183X, 6 p.Article

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemiaBARNES, David J; PALAIOLOGOU, Danai; PANOUSOPOULOU, Eleni et al.Cancer research (Baltimore). 2005, Vol 65, Num 19, pp 8912-8919, issn 0008-5472, 8 p.Article

Page / 5